Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Sarno, Giovanna; Lagerqvist, Bo; Fröbert, Ole; Nilsson, Johan; Olivecrona, Göran; Ömerovic, Elmir; Saleh, Nawzad; Venetzanos, Dimitris; James, Stefan

doi:10.1093/eurheartj/ehr479

Cited by 335 publications

(186 citation statements)

References 38 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…The differences between the study groups decreased over time, and at 1 year, the rates were very low and were similar in the two groups. The low rate of stent thrombosis is consistent with the frequent use of new-generation drug-eluting stents 15,16 and potent platelet inhibition.…”

Section: Discussionsupporting

confidence: 56%

Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 56%

Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…20 In recent years, new-generation DES replaced early-generation DES because of improved stent design, similar or superior antirestenotic efficacy, and consistently lower rates of late ST. 21,22 Both zotarolimus and everolimus are sirolimus analogues, in which the hydroxyl group at position 40 of the sirolimus has been replaced by a lipophilic tetrazole and hydroxyethyl group, respectively. Antiproliferative agents are released from biocompatible durable polymers in both devices: the BioLink polymer in R-ZES, which consists of 3 polymers (a hydrophobic C10 polymer, a hydrophilic C19 polymer, and water-soluble polyvinyl pyrrolidinone) and a 2-layer polymer system in EES, with an acrylate primer and a fluorinated copolymer.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Piccolo

Stefanini

Franzone

et al. 2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R-ZES compared with EES in patients undergoing percutaneous coronary intervention. Methods and Results-A systematic literature search of electronic resources was performed using specific search terms until September 2014. Random-effects meta-analysis was performed comparing clinical outcomes between patients treated with R-ZES and EES up to maximum available follow-up. The primary efficacy end point was targetvessel revascularization.

show abstract

“…Bifurcation lesions (BLs) account for 15 to 20 % of percutaneous coronary interventions (PCI) [1,2]. The European Bifurcation Club recommends a single-stent approach with provisional side branch stenting as the preferred treatment for BLs [3].…”

Section: Introductionmentioning

confidence: 99%

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

et al. 2012

View full text Add to dashboard Cite

Aims Percutaneous coronary intervention (PCI) of a bifurcation lesion (BL) is still associated with poorer clinical outcomes when compared with PCI of a non-BL. Therefore, several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA), were developed to improve clinical outcomes. We investigated 6-month clinical outcomes after placement of a Tryton stent in 91 patients treated for 93 BLs in our centre. Methods and results All consecutive patients who have undergone PCI of a BL treated with the Tryton stent in our centre were included. Outcomes were defined as any death, cardiac death, myocardial infarction (MI), any revascularisation, ischaemia-driven target vessel revascularisation (TVR), ischaemia-driven target lesion revascularisation (TLR), stent thrombosis, and target vessel failure (TVF; composite of cardiac death, MI, and ischaemia-driven TVR). Event rates were estimated using the Kaplan-Meier method. Thirty-eight (42 %) patients with acute coronary syndrome (ACS) were included (16 % ST-segment elevation MI (STEMI)). The 6-month event rates were 5.4 % (death), 4.3 % (cardiac death), 2.2 % (MI), 4.5 % (any revascularisation), 4.5 % (TVR), 4.5 % (TLR) and 9.7 % (TVF). ConclusionIn a real-world all-comers single-centre registry, the use of the Tryton Side Branch Stent was associated with acceptable procedural and promising clinical outcomes at 6 months, including ACS and STEMI patients.

show abstract

Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Abstract: Percutaneous coronary intervention with n-DES is associated with a 38% lower risk of clinically meaningful restenosis, a 43% lower risk of definite ST, and a 23% lower risk of death compared with o-DES in this observational study from a large real-world population.

Cited by 335 publications

References 38 publications

Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction

Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

Contact Info

Product

Resources

About